No registrations found.
ID
Source
Brief title
Health condition
Diabetes Mellitus type 2 (DM type II)
Sponsors and support
Intervention
Outcome measures
Primary outcome
Glucose and insulin concentrations in blood
Secondary outcome
Glucagon-like peptide-1 concentrations and dipeptidyl peptidase IV activity in blood
Background summary
High coffee consumption is associated with a lower risk of type 2 diabetes. Similar associations are observed for caffeinated and decaffeinated coffee, suggesting that coffee components other than caffeine have beneficial effects on glucose homeostasis. Chlorogenic acid and trigonelline are major components in coffee and may be partly responsible for improved glucose tolerance following coffee consumption. The objective of this study is to test whether chlorogenic acid and trigonelline ingestion acutely reduce postprandial glucose concentrations in humans. The study is a randomized cross-over trial in 20 overweight men including 4 treatments: decaffeinated coffee, chlorogenic acid, trigonelline, and placebo. Acute effects on glucose and insulin responses following an oral glucose tolerance test will be examined.
Study objective
Intake of chlorogenic acid and trigonelline reduce postprandial glucose concentrations during an oral glucose tolerance test relative to placebo.
Intervention
All participants will receive four treatments in random order, on four different days:
1. Decaffeinated coffee;
2. Chlorogenic acid.
3. Trigonelline.
4. Mannitol (placebo).
All treatments will be ingested before an oral glucose tolerance test. Blood samples will be taken on 7 occasions on each study day. Treatments will be double blind, except for the decaffeinated coffee treatment.
Margreet R. Olthof
De Boelelaan 1085
Amsterdam 1081 HV
The Netherlands
+31 205982522
margreet.olthof@falw.vu.nl
Margreet R. Olthof
De Boelelaan 1085
Amsterdam 1081 HV
The Netherlands
+31 205982522
margreet.olthof@falw.vu.nl
Inclusion criteria
1. Apparently healthy males;
Acute effects of coffee and major coffee components on glucagon-like peptide 1 response and glucose tolerance in humans;
2. Age at screening: 18 years and above;
3. Body mass index (BMI) between 25.0 and 35.0 kg/m2;
4. Regular coffee consumer;
5. Willing to restrict coffee consumption during the study to max. 1 cup per day;
6. Voluntary participation;
7. Willing not to be blood or plasmaferese donor from 4 weeks before the start of the study until the end of study.
Exclusion criteria
1. Women;
2. Smokers;
3. Diabetics;
4. Blood sampling is considered too difficult (assessed during pre-study screening);
5. Any chronic or acute disease;
6. Hypertension criteria for moderate hypertension WHO 2003;
7. Medical history or surgical events known to interfere with the study;
8. Alcohol consumption > 28 consumptions per week;
9. Self reported weight loss or gain > 2 kg in the month prior to screening;
10. Any special diet;
11. Participation in any other intervention trial up to 3 months before and during this study;
12. Use of medication known to interfere with the study outcome;
13. Exercising more than 4 hours vigorously per week.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1020 |
| NTR-old | NTR1051 |
| Other | : 2006.11.020/2946308 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |